CL2022002251A1 - Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos - Google Patents

Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos

Info

Publication number
CL2022002251A1
CL2022002251A1 CL2022002251A CL2022002251A CL2022002251A1 CL 2022002251 A1 CL2022002251 A1 CL 2022002251A1 CL 2022002251 A CL2022002251 A CL 2022002251A CL 2022002251 A CL2022002251 A CL 2022002251A CL 2022002251 A1 CL2022002251 A1 CL 2022002251A1
Authority
CL
Chile
Prior art keywords
methods
tslp antibody
human anti
antibody formulations
tslp
Prior art date
Application number
CL2022002251A
Other languages
English (en)
Inventor
Roschen Lauren
Litowski Jennifer
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2022002251A1 publication Critical patent/CL2022002251A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan en la presente composiciones que comprenden más de aproximadamente 100 mg/mL de un anticuerpo anti-TSLP, un tensioactivo, prolina y un amortiguador que comprende más de aproximadamente 100 mg/mL de un anticuerpo anti-TSLP, un tensioactivo, prolina y un amortiguador. Además, se proporcionan métodos para tratar una enfermedad inflamatoria en un sujeto.
CL2022002251A 2020-02-18 2022-08-18 Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos CL2022002251A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062978201P 2020-02-18 2020-02-18

Publications (1)

Publication Number Publication Date
CL2022002251A1 true CL2022002251A1 (es) 2023-04-14

Family

ID=74860588

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002251A CL2022002251A1 (es) 2020-02-18 2022-08-18 Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos

Country Status (19)

Country Link
US (1) US20230081261A1 (es)
EP (1) EP4106811A1 (es)
JP (1) JP2023513833A (es)
KR (1) KR20220143699A (es)
CN (1) CN115151276A (es)
AR (1) AR121368A1 (es)
AU (1) AU2021221998A1 (es)
BR (1) BR112022016456A2 (es)
CA (1) CA3167975A1 (es)
CL (1) CL2022002251A1 (es)
CO (1) CO2022013251A2 (es)
CR (1) CR20220465A (es)
IL (1) IL295511A (es)
JO (1) JOP20220193A1 (es)
MX (1) MX2022010120A (es)
PE (1) PE20230115A1 (es)
TW (1) TW202144004A (es)
UY (1) UY39089A (es)
WO (1) WO2021168100A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4145105A1 (de) * 2021-09-06 2023-03-08 Anacyte Laboratories GmbH Lösung für die asservierung von zellen
CN118215681A (zh) * 2021-09-18 2024-06-18 江苏康宁杰瑞生物制药有限公司 包含pd-l1抗原结合片段的组合物及其用途
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂
WO2024092064A1 (en) * 2022-10-26 2024-05-02 Amgen Inc. Anti-tslp antibody compositions and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
TW201018482A (en) 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
CA2779384C (en) 2009-11-04 2018-02-27 Schering Corporation Engineered anti-tslp antibody
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
AT510032B1 (de) 2010-11-30 2012-01-15 Steiner Erwin Ing Montageeinrichtung für fassadenelemente
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
WO2016142426A1 (en) 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited Tslp binding proteins
UY36889A (es) 2015-09-09 2017-04-28 Novartis Ag Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
MA48461A (fr) * 2017-04-28 2020-03-04 Amgen Inc Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
WO2019094138A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
WO2019178151A1 (en) 2018-03-13 2019-09-19 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
WO2020081479A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Drug delivery device having damping mechanism
EP3866889A1 (en) 2018-10-15 2021-08-25 Amgen Inc. Platform assembly process for drug delivery device

Also Published As

Publication number Publication date
UY39089A (es) 2021-08-31
CN115151276A (zh) 2022-10-04
CO2022013251A2 (es) 2022-12-20
CA3167975A1 (en) 2021-08-26
TW202144004A (zh) 2021-12-01
IL295511A (en) 2022-10-01
JP2023513833A (ja) 2023-04-03
CR20220465A (es) 2023-03-30
KR20220143699A (ko) 2022-10-25
JOP20220193A1 (ar) 2023-01-30
US20230081261A1 (en) 2023-03-16
AU2021221998A1 (en) 2022-09-15
AR121368A1 (es) 2022-06-01
MX2022010120A (es) 2022-09-05
PE20230115A1 (es) 2023-01-27
BR112022016456A2 (pt) 2022-10-04
EP4106811A1 (en) 2022-12-28
WO2021168100A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
CO2022013251A2 (es) Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos
Hart et al. The immunity conferred by effective BCG and vole bacillus vaccines, in relation to individual variations in induced tuberculin sensitivity and to technical variations in the vaccines
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
BRPI0210568B8 (pt) conjugado, uso de um conjugado, e, composição farmacêutica
BRPI0809663A8 (pt) Composição de vírus vivo atenuado, usos da mesma, métodos de diminuição da inativação de vírus vivo atenuado, e kit para diminuir a inativação de uma composição de vírus vivo atenuado.
ECSP066294A (es) Un conjugado citotóxico ca6 antígeno-específico y métodos para utilizar el mismo
CL2008001984A1 (es) Formulacion de anticuerpo anti-cd20; y su uso para tratar enfermedades que implican celulas que expresan cd20 en un mamifero.
SV2006002174A (es) Composicion de anticuerpo her2
EA200401522A1 (ru) Противотуберкулёзный препарат: композиции и способы
CR7786A (es) Anticuerpos neutralizantes contra gdf-8 y el uso de los mismos
BRPI0514982A (pt) adjuvante de glicosilceramida para antìgenos de sacarìdeo
AR043144A1 (es) Formulacion de inmunoglobulina y metodo de preparacion de la misma
GT200200114A (es) Champues con alcohol de behenilo
AR054805A1 (es) Composiciones topicas para el tratamiento de la piel
AR122060A1 (es) Formulaciones de anticuerpos anti-il-33 y métodos de uso de las mismas
AR117407A1 (es) Formulaciones acuosas estables de anticuerpos anti-tau
AR077611A1 (es) Metodo y conjunto de elementos ( kit) para tratar la adiccion a la nicotina. combinacion. uso.
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
CL2023002602A1 (es) Uso de células madre mesenquimales sobreexpresoras de pacer para el tratamiento de enfermedades con origen y/o componente inflamatorio
Carluccio et al. Corpus Luteum Sensitivity to PGF2 [alpha] Administration in the Martina Franca Jenny
DE602004015141D1 (de) Modifizierte ganzzell-, zellextrakt- und omv-basierte impfstoffe
BR112023002926A2 (pt) Agentes terapêuticos inaláveis
CO2021012209A2 (es) Composición para cuidado oral
Kuk et al. 2002-2011 Yılları Arasında Erciyes Üniversitesi Tıp Fakültesi Tıbbi Parazitoloji Anabilim Dalına Başvuran Hastalarda Demodex spp. Görülme Sıklığı
EA200401523A1 (ru) Способы применения и композиции для диагностики и лечения инфекционного заболевания